TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7743301

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg every morning for 3 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2040103

Group type: EXPERIMENTAL
Intervention: 30 mg of prednisone for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6165428

Group type: EXPERIMENTAL
Intervention: Partially purified human leucocyte interferon (PIF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preparation purified by passage twice through a monoclonal antibody affinity chromatography column (NK21F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 0
Study: 31759471

Group type: EXPERIMENTAL
Intervention: Coordinated Knowledge System (CKS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Survey plus Practice Guidelines (SPG)
Number of subjects: 17
Study: 28137530

Group type: EXPERIMENTAL
Intervention: Spiritist 'passe'
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 41

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 41
Study: 25995489

Group type: EXPERIMENTAL
Intervention: Multimodal pain regimen with periarticular injection (PAI)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA)
Number of subjects: 84
Study: 24338139

Group type: EXPERIMENTAL
Intervention: Milrinone (50 μg/kg intravenously followed by 24 hours infusion at 0.5 μg/kg/min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study: 21357861

Group type: EXPERIMENTAL
Intervention: Rubber dam
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Isolite i2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Coolex
Number of subjects: 5

Group type: COMPARATOR
Intervention: Nonisolated control
Number of subjects: 5
Study: 20184048

Group type: EXPERIMENTAL
Intervention: Endovascular repair (endovascular first)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Open repair (normal care)
Number of subjects: 600
Study: 17664328

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) and Lamivudine (3TC) administered once daily (QD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) and Lamivudine (3TC) administered twice daily (BID)
Number of subjects: 27
Study: 15222056

Group type: EXPERIMENTAL
Intervention: Postoperative gastrointestinal decompression
Number of subjects: 368

Group type: COMPARATOR
Intervention: No postoperative gastrointestinal decompression
Number of subjects: 368
Study: 12391662

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with mesh prosthesis and general anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study: 9698958

Group type: EXPERIMENTAL
Intervention: Haemofiltration with saline added in a ratio of 5:1 of estimated blood volume
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Haemofiltration with saline added in a ratio of 1:1 of estimated blood volume
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 16
Study: 8728789

Group type: EXPERIMENTAL
Intervention: Steatocrit
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sudan III
Number of subjects: 50

Group type: COMPARATOR
Intervention: Van de Kamer test
Number of subjects: 50
Study: 2677227

Group type: EXPERIMENTAL
Intervention: Highly purified pork insulin (Nordisk, Denmark)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Human insulin of recombinant DNA origin (Eli Lilly, USA)
Number of subjects: 29
Study: 332471

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31125385

Group type: EXPERIMENTAL
Intervention: Electrical stimulation at frequencies of 0.5Hz, 1.1Hz, 1.6Hz (each with 500 stimuli)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 90
Study: 27809613

Group type: EXPERIMENTAL
Intervention: Complete enteral feed (CEF) with expressed breast milk (EBM), n=51
Number of subjects: 103

Group type: COMPARATOR
Intervention: Minimal enteral feed (MEF) supplemented with intravenous fluid (IVF), n=52
Number of subjects: 103
Study: 25868876

Group type: EXPERIMENTAL
Intervention: TriGuard™ Embolic Deflection Device (EDD)
Number of subjects: 37
Study: 24195786

Group type: EXPERIMENTAL
Intervention: Imidapril (10 - 20 mg once daily)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Ramipril (5 - 10 mg once daily)
Number of subjects: 176
Study: 22428349

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 60
Study: 19957508

Group type: EXPERIMENTAL
Intervention: Combined intercostal nerves block-sevoflurane used inhalation anesthesia with laryngeal mask ventilation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane used inhalation anesthesia with laryngeal mask ventilation (Control Group)
Number of subjects: 60
Study: 16886116

Group type: EXPERIMENTAL
Intervention: Serotonin transporter short/short (S/S) genotype
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serotonin transporter allele S genotype
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: S/S genotype in patients with less than 40% of markers evacuated within 72 h
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 54
Study: 15549276

Group type: EXPERIMENTAL
Intervention: Cocoa powder (11.6 g)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Caffeine (19 mg) and theobromine (250 mg) combination
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Milk chocolate (methylxanthine doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dark chocolate (methylxanthine doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: White chocolate
Number of subjects: 42
Study: 11510029

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,200 mg/m² IV on days 1 and 8) plus Carboplatin (AUC 5 IV on day 1)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Cisplatin (60 mg/m² IV on day 1) plus Etoposide (120 mg/m² IV on day 1 and 100 mg orally on days 2 and 3)
Number of subjects: 77
Study: 9242944

Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis with elevated modeled V/W ratios (0.64)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional hemodialysis without elevated modeled V/W ratios (0.53)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Access flow
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recirculation measurement by slow flow/clamp technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Follow-up modeling in high V/W patients
Number of subjects: 20
Study: 8488028

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet (gluten-free diet supplemented by gluten)
Number of subjects: 50
Study: 3320187

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 0
Study: 28874323

Group type: EXPERIMENTAL
Intervention: Probiotic and zinc
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Probiotic and placebo
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Placebo and zinc
Number of subjects: 620

Group type: COMPARATOR
Intervention: Two placebos
Number of subjects: 620
Study: 27180949

Group type: EXPERIMENTAL
Intervention: Stretching plus manually applied manipulation (MAM)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Stretching plus instrument‐applied manipulation (IAM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Stretching (control)
Number of subjects: 65
Study: 25150180

Group type: EXPERIMENTAL
Intervention: Plasmakinetic enucleation of the prostate (PKEP)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Plasmakinetic resection of the prostate (PKRP)
Number of subjects: 310
Study: 23808896

Group type: EXPERIMENTAL
Intervention: Integrated care (IC) provided by a multidisciplinary team for 52 weeks
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Integrated care (IC)
Number of subjects: 196
Study: 19933225

Group type: EXPERIMENTAL
Intervention: Genous stent
Number of subjects: 193

Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 193
Study: 18487758

Group type: EXPERIMENTAL
Intervention: Electronic Disease Surveillance System for monitoring blood glucose data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring blood glucose levels
Number of subjects: 0
Study: 16014875

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Job Readiness (JR) (attention control)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard Referral
Number of subjects: 302
Study: 12793556

Group type: EXPERIMENTAL
Intervention: Early reconstruction (within 2 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Delayed reconstruction (8 to 12 weeks)
Number of subjects: 31
Study: 11066188

Group type: EXPERIMENTAL
Intervention: Investigational approaches toward a new classification of patients with early synovitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical treatment approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic predisposition awareness and manipulation of biological pathways
Number of subjects: 0
Study: 9001663

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day i.v.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 28
Study: 1619181

Group type: EXPERIMENTAL
Intervention: Iodine-enriched egg (1 egg/day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Diet control (no egg)
Number of subjects: 103
Study: 6394004

Group type: EXPERIMENTAL
Intervention: Cefaclor, 250 mg twice daily for 10 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin, 500 mg four times daily for 10 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefaclor and Ampicillin (both regimens)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 100
Study: 29401202

Group type: EXPERIMENTAL
Intervention: One session of plyometric training (1SPT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Two sessions of plyometric training (2SPT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plyometric training (PT)
Number of subjects: 30
Study: 27371157

Group type: COMPARATOR
Intervention: AQW051 100mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: AQW051 7.5mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 22763117

Group type: EXPERIMENTAL
Intervention: Hip-adductor strengthening programme using elastic bands
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 22392168

Group type: EXPERIMENTAL
Intervention: Breast milk (either breastfed or bottle-fed) during heel lance
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sucrose administered before heel lance
Number of subjects: 71
Study: 20435991

Group type: EXPERIMENTAL
Intervention: small-molecule glycoprotein IIb/IIIa inhibitors (smGPIs)
Number of subjects: 2040

Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 2040
Study: 18687841

Group type: EXPERIMENTAL
Intervention: Iodine-based solution preparation for 90 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clear fluid antiseptic preparation for 60 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clear fluid antiseptic preparation for 90 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iodine-based solution preparation for 60 seconds
Number of subjects: 0
Study: 16850654

Group type: EXPERIMENTAL
Intervention: Education program and problem solving work group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 12783111

Group type: EXPERIMENTAL
Intervention: Vitamin C 2g/day plus vitamin E 400 IU/day (group B)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vitamin C 2g/day plus vitamin E 800 IU/day (group C)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vitamin C 2g/day (group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No antioxidants (controls, group D)
Number of subjects: 41
Study: 11039375

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid conduit
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard repair (end-to-end or nerve graft)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nerve graft
Number of subjects: 98
Study: 8853850

Group type: EXPERIMENTAL
Intervention: White males
Number of subjects: 64

Group type: COMPARATOR
Intervention: Black males
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: White females
Number of subjects: 64

Group type: COMPARATOR
Intervention: Black females
Number of subjects: 64
Study: 1500891

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6425231

Group type: EXPERIMENTAL
Intervention: GP 53.633 (GP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30454876

Group type: EXPERIMENTAL
Intervention: Agent support
Number of subjects: 56

Group type: COMPARATOR
Intervention: No support
Number of subjects: 56
Study: 29869004

Group type: EXPERIMENTAL
Intervention: Intramuscular supplementation of vitamin D with a single dose of 600,000 IU cholecalciferol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (oral supplementation limited to 1400 IU of vitamin D)
Number of subjects: 20
Study: 27160498

Group type: EXPERIMENTAL
Intervention: Integrated nutritional therapy (oral, enteral, and parenteral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional strategy based on disease-specific guidelines
Number of subjects: 0
Study: 25494823

Group type: EXPERIMENTAL
Intervention: Ciclosporin A (CsA) monitored by residual NFAT-regulated gene expression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciclosporin A (CsA) monitored by trough levels
Number of subjects: 0
Study: 22167539

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 266

Group type: COMPARATOR
Intervention: Xalatan® (latanoprost 0.005%)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% and Xalatan®
Number of subjects: 266
Study: 21117407

Group type: EXPERIMENTAL
Intervention: 1 microg ACTH stimulation test
Number of subjects: 10

Group type: COMPARATOR
Intervention: 250 microg ACTH stimulation test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both tests (1 microg and 250 microg ACTH)
Number of subjects: 10
Study: 17435458

Group type: EXPERIMENTAL
Intervention: PUFAs alone
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: PUFAs + micronutrients
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 10953902

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day for 5 days to 3 g/day for 9 weeks)
Number of subjects: 48
Study: 9105072

Group type: EXPERIMENTAL
Intervention: Surfactant (up to four doses of 100 mg phospholipids/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (standard therapy only)
Number of subjects: 59
Study: 1337163

Group type: EXPERIMENTAL
Intervention: Low calcium PD fluid (calcium 1.25 mmol/l) with oral calcium carbonate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard PD solution (calcium 1.75 mmol/l) with calcium carbonate plus aluminium hydroxide phosphate binders
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low calcium PD fluid (calcium 1.25 mmol/l)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard PD solution (calcium 1.75 mmol/l)
Number of subjects: 50
Study: 2435043

Group type: EXPERIMENTAL
Intervention: Oral phenoxybenzamine (10 mg b.i.d.; n = 21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo tablets (n = 22)
Number of subjects: 43
Study: 29634086

Group type: EXPERIMENTAL
Intervention: Multilevel cardiovascular disease prevention program (6 months, twice-weekly exercise, nutrition, and heart health classes)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Education-only control program (didactic healthy lifestyle classes once a month for 6 months)
Number of subjects: 194
Study: 27792801

Group type: EXPERIMENTAL
Intervention: Methacrylate-based composite resin (Filtek Z250)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Silorane-based composite resin (Silorane P90)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Methacrylate-based composite resin (Filtek Z250) with oxalic acid-based desensitizing agent (Desenssiv, SSWhite)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Silorane-based composite resin (Silorane P90) with oxalic acid-based desensitizing agent (Desenssiv, SSWhite)
Number of subjects: 31
Study: 24826855

Group type: EXPERIMENTAL
Intervention: Pelvic ultrasound simulators (PS)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Live models (LM)
Number of subjects: 134
Study: 22713543

Group type: EXPERIMENTAL
Intervention: High-frequency γ-oscillations originating in fronto-parietal networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attentional networks
Number of subjects: 0
Study: 20067954

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) alone
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus daclizumab (DZB)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 18472355

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional Radiotherapy (CRT)
Number of subjects: 221
Study: 15696400

Group type: EXPERIMENTAL
Intervention: Sotalol (1.5 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flecainide (2 mg/kg)
Number of subjects: 12
Study: 12889588

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment for trichomoniasis
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment for bacterial vaginosis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 10574370

Group type: EXPERIMENTAL
Intervention: 100 microM roscovitine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 8
Study: 9592308

Group type: EXPERIMENTAL
Intervention: Sulperazone (SPZ)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Tienam (TIM)
Number of subjects: 73
Study: 2048463

Group type: EXPERIMENTAL
Intervention: Mizes Anorectic Cognitions (MAC) questionnaire
Number of subjects: 100
Study: 31781880

Group type: EXPERIMENTAL
Intervention: Topically applied coenzyme Q10 (CoQ10)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 93
Study: 31512143

Group type: EXPERIMENTAL
Intervention: TurboCBD™ 90 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: 90 mg control
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28223262

Group type: EXPERIMENTAL
Intervention: SMS text message intervention
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Patient survey (paper or telephone interview)
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Demographic factors
Number of subjects: 1139
Study: 25579777

Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide pneumococcal vaccine (PPV23)
Number of subjects: 152723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152723
Study: 23662815

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Motivational incentives (reward, response cost)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline (low incentive)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 28
Study: 21899812

Group type: EXPERIMENTAL
Intervention: Cryotherapy using liquid nitrogen
Number of subjects: 240

Group type: COMPARATOR
Intervention: Salicylic acid (50% self-treatment)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Salicylic acid
Number of subjects: 240
Study: 19473560

Group type: EXPERIMENTAL
Intervention: Intraarticular injection with triamcinolone hexacetonide 60 mg and xylocaine chloride 2% (IAI group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular injection of triamcinolone acetonide 60 mg and xylocaine chloride 2% (IM group)
Number of subjects: 60
Study: 17636114

Group type: EXPERIMENTAL
Intervention: Lower third of the change in moderate-to-vigorous physical activity (PA)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Upper third of the change in moderate-to-vigorous physical activity (PA)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Rare allele carriers of SNPs
Number of subjects: 479
Study: 16299426

Group type: EXPERIMENTAL
Intervention: Anxiety disorders (panic disorder, posttraumatic stress disorder, social phobia)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Generalized anxiety disorder
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Anxiety disorders overall
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Anxiety disorders (combined with chronic physical illness, major depression, and socioeconomic factors)
Number of subjects: 480
Study: 12374678

Group type: EXPERIMENTAL
Intervention: Oral alpha-difluoromethylornithine (DFMO) 0.5 g/m(2)/day for 6 months
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 10075594

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 348
Study: 7478691

Group type: EXPERIMENTAL
Intervention: Real heelstick condition
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham heelstick condition
Number of subjects: 48
Study: 2154068

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin infusions (500 mg/kg x 3 doses, followed by 250 mg/kg x 2 doses at 2-week intervals)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 34
Study: 7276205

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distalgesic (paracetamol and dextropropoxyphene)
Number of subjects: 0
Study: 30951917

Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Both CEA and CAS
Number of subjects: 314